There were no significant differences in age, obesity, hormonal status, histology, histopathological grade, Ki67, AR expression, positive lymph node involvement, tumor subtype (TN or HER2+), chemotherapy regimen received or pCR rate between positive and negative PD-L1 expression. The gene discussed is ERBB2; the disease is neoplasm.